Dr. Kenderian is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
200 1st St Sw
Rochester, MN 55905Phone+1 507-284-2511
Education & Training
- University of PennsylvaniaTranslational Research Program, Center for Cellular Immunotherapies, 2013 - 2016
- Penn MedicinePost-Doctoral Fellowship, 2013 - 2015
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2012 - 2013
- Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 2010 - 2013
- McLaren Health Care/Flint/MSUChief Residency, Internal Medicine, 2008 - 2009
- McLaren Health Care/Flint/MSUResidency, Internal Medicine, 2006 - 2009
- University of Baghdad College of MedicineClass of 2003
Certifications & Licensure
- MN State Medical License 2010 - 2026
- PA State Medical License 2013 - 2014
- MI State Medical License 2006 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Innovation Award – Research Department of Medicine, Mayo Clinic, 2016
- Career Development Award Department of Medicine, Mayo Clinic, 2015-2016
- Best Abstract Award American Society for Blood and Marrow Transplantation, 2015-2016
- Join now to see all
Publications & Presentations
PubMed
- Zirconium- 89 Labeled Antibody K1-70 for PET Imaging of Thyroid-stimulating Hormone Receptor Expression in Thyroid Cancer.Ephraim E Parent, Justyna J Gleba, Joshua A Knight, Saad J Kenderian, John A Copland 3rd
Molecular Imaging and Biology. 2024-10-01 - 1 citationsACT To Sustain: Adoptive Cell Therapy To Sustain Access to Non-Commercialized Genetically Modified Cell Therapies.Rebecca A Gardner, Claire White, Magdi Elsallab, Stephanie Farnia, Ellen Fraint
Transplantation and Cellular Therapy. 2024-08-01 - 3 citationsAllogeneic Hematopoietic Stem Cell Transplantation in the Outpatient Setting: The Mayo Clinic Experience.Sachi Singhal, Salwa S Saadeh, Urshila Durani, Ankit Kansagra, Hassan B Alkhateeb
Transplantation and Cellular Therapy. 2023-03-01
Journal Articles
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapiesRuella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morri..., J Clin Invest, 1/29/2016
- Activity of anti-CD19 Chimeric Antigen Receptor T cells in Combination with Ibrutinib in Mouse Xenografts of Mantle Cell LymphomaRuella M, Kenderian SS, Shestove O, Fraietta J, Qayyum S, Zhang Q, Maus MV, Liu X, Nunez-Cruz S, Klichinsky M, Kawalekar O, Milone M, Lacey S, Mato A, Schuster S, Kalo..., Clin Cancer Res, 1/27/2016
- The microbiome and immune regulation after transplantationTabibian JH, Kenderian SS, Transplantation, 1/11/2016
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Targeting Cancer Associated Fibroblasts in the Bone Marrow Prevents Resistance to Chimeric Antigen Receptor T Cell Therapy in Multiple MyelomaSaad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of ProgressionSaad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Targeting of CD19 By Tafasitamab Does Not Impair CD19 Directed Chimeric Antigen Receptor T Cell Activity in VitroSaad S. Kenderian, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Lectures
- Preclinical Modeling of CART Cells and Combination ImmunotherapySan Francisco, CA - 1/1/2017
- Chimeric antigen receptor T cell therapy: where are we now?Rochester, MN - 1/1/2016
- Chimeric Antigen Receptor T Cell Therapy: Building Smarter CARsRochester, MN - 1/1/2016
- Join now to see all
Press Mentions
- Addressing the Challenges of Chimeric Antigen Receptor-T Cell TherapyAugust 2nd, 2022
- The Team That Kept Translational Science on the Fast Track to Curb COVID-19 PneumoniaJune 22nd, 2021
- Cancer to COVID-19June 22nd, 2021
- Join now to see all
Professional Memberships
- Member
- Member
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: